Mirum doubles down on diversified rare disease strategy

With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.

By Alexandra Pecci • Feb. 3, 2026

AI regulation lags despite entering higher-risk patient care

While more pharma companies launch DTC platforms, states, not the federal government, are providing guardrails to protect patient privacy and safety.

By Kelly Bilodeau • Feb. 2, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

By Meagan Parrish • Jan. 30, 2026

How Big Pharma is navigating a $300 billion patent cliff

Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses. 

By Kelly Bilodeau • Jan. 30, 2026

Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.

By Alexandra Pecci • Jan. 29, 2026

Politicization runs deeper than ever at FDA, risking long-term impacts

Wide-ranging shifts at the FDA have set the stage for decisions that drag the agency through the political mud, according to an economist and public policy expert.

By Michael Gibney • Jan. 29, 2026

Has Novavax cracked the code for survival in the vaccine arena?

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.

By Meagan Parrish • Jan. 28, 2026

Biopharma layoffs surged last year, but 2026 is a chance to turn the page

Companies are adjusting to turbulence in the U.S. market, and more traditional job loss factors will likely be at play in the coming year.

By Kelly Bilodeau • Jan. 26, 2026

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

By Alivia Kaylor • Jan. 23, 2026

US drug pricing policies are ‘red lights’ for investors, and China beckons

Pricing policies like most-favored nation and the Inflation Reduction Act, as well as a destabilized FDA, are pushing investors to look outside the U.S.

By Michael Gibney • Jan. 22, 2026

Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.

By Kelly Bilodeau • Jan. 21, 2026

Lilly, Takeda targeted by legal strategy usually reserved for the mob

A case targeting alleged fraud around the safety risk of a blockbuster diabetes drug is leveraging the RICO pathway and could have a ripple effect in pharma.

By Kelly Bilodeau • Jan. 20, 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.

By Alexandra Pecci • Jan. 20, 2026

Trump unveils healthcare affordability plan

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench Trump’s drug pricing deals.

By Rebecca Pifer Parduhn • Jan. 16, 2026

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

The “trauma” faced by pharma execs in 2025 kept M&A at a low simmer, experts say, but as predictability returns, dealmaking could be turned up.

By Michael Gibney • Jan. 15, 2026

Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs

The GLP-1 giants are the first to try out this new model, but more companies may follow. 

By Kelly Bilodeau • Jan. 14, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class. 

By Kelly Bilodeau • Jan. 12, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

The wellness industry is HHS’ new belle of the ball

Congressional leaders and health experts are sounding the alarm about potential conflicts of interest among the agency’s new leaders.

By Kelly Bilodeau • Jan. 8, 2026

5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

C-suite priorities give a sneak peek into AI’s pharma future

While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.

By Kelly Bilodeau • Jan. 7, 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

How pharma leaders believe the regulatory and investment market landscape will change in 2026. 

By Meagan Parrish • Jan. 6, 2026

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026